Which funds bought or sold TXG in Q3 2026?
10X Genomics Inc. 2 funds bought, 6 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$236M. See also what famous investors say about TXG.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- VikingNEW+$68M
- MaverickNEW+$49M
- ARK−$337M
- Citadel−$250M
- Point72−$161M
- Vanguard−$96M
- Renaissance−$66M
- DuquesneOUT−$15M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (2)
Sold (6)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| ARK Growth / crossover | Trimmed-37.3% | −$337M | $567M |
| Citadel Quant & multi-strategy | Trimmed-99.4% | −$250M | $1M |
| Point72 Quant & multi-strategy | Trimmed-96% | −$161M | $7M |
| Vanguard Index giant | Trimmed-15.3% | −$96M | $534M |
| Renaissance Quant & multi-strategy | Trimmed-91.8% | −$66M | $6M |
| Duquesne Family office & foundation | Sold out | −$15M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.